若生智能
Drug Database
PA

pancrelipase (Ultrase MT20 / Ultrase MT / Ultresa)

✓ Approved

Adare Pharma Solutions · PNLIP

什么是 pancrelipase？

pancrelipase 是一种治疗药物，由Adare Pharma Solutions研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Ultrase MT20, Ultrase MT, Ultresa
公司Adare Pharma Solutions
分子靶点PNLIP
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Adare Pharma Solutions

作用机制

分子靶点

pancrelipase 作用于 1 个分子靶点：

PNLIPpancreatic lipase (PL, PNLIPD)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pancrelipase 针对 3 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
InvestigationsFaecal fat increased✓ Approved
Gastrointestinal disordersSteatorrhoea✓ Approved
Gastrointestinal disordersPancreatic failure✓ Approved

相关研究文献

PubMedObesity reviews : an official journal of the International Association for the Study of Obesity2026-07-27

Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Shegena Efrata A EA, Kiflu Mekdes M, Ahmed Muktar M, Bhagavathula Akshaya Srikanth AS et al.

Glucagon-like peptide 1 (GLP-1) agonists are widely used for obesity management in patients with or without diabetes. However, treatment persistence is often limited due to adverse drug reactions (ADRs). Understanding adherence patterns in randomized controlled trials (RCTs) is crucial for predicting real-world treatment acceptance. To estimate the pooled nonadherence rates and reasons for nonadherence to GLP-1 agonists in overweight or patients with obesity participating in RCTs. A systematic review and meta-analysis of RCTs was conducted to evaluate nonadherence to GLP-1 receptor agonists. A literature search was performed in PubMed, Embase, and Web of Science from inception to October 2, 2024. Studies were included if they evaluated GLP-1 receptor agonists for overweight or obesity management and reported adherence outcomes. The pooled RR for nonadherence to GLP-1 receptor agonists was 0.63 (95% CI: 0.48, 0.82, p = 0.01), indicating a 37% lower risk of nonadherence compared with the control group. However, ADR-induced nonadherence was significantly higher in the GLP-1 group (RR: 2.29 [95% CI: 1.47, 3.56, p = 0.04]), particularly due to gastrointestinal side effects. Nonadherence due to loss to follow-up was lower in the GLP-1 group (RR: 0.43 [95% CI: 0.27, 0.71, p = 0.18]). GLP-1 receptor agonists were associated with a lower overall nonadherence rate in RCTs compared with control treatments, suggesting higher persistence. However, ADR-related nonadherence was significantly higher, particularly due to gastrointestinal side effects. These findings highlight the need for strategies to improve treatment tolerability and adherence in real-world settings.

PMID 42503568
阅读全文 →
PubMedJournal of managed care & specialty pharmacy2026-07-27

Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.

DiStefano Michael J MJ, Zon Juliet J, Olson Erik G EG, Levy Joseph F JF et al.

Although many people discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the reasons for discontinuation are unclear. To identify self-reported reasons for GLP-1 RA discontinuation among US adults. Cross-sectional survey of US adults fielded in June 2025 using Ipsos Omnibus and incorporating survey weights calibrated to census benchmarks. We included individuals who initiated a GLP-1 RA between January 2022 and June 2025 and subsequently discontinued therapy. Outcomes included duration of use, self-reported reason(s) for discontinuation, medication source, out-of-pocket payment, and insurance coverage. Descriptive statistics and chi-square tests for statistical significance were used. Of 7,035 individuals screened, 440 respondents met eligibility criteria and completed the survey. Of these 440 participants, 51.1% were female, 42.3% were aged between 18 and 34 years, and 23.8% reported having type 2 diabetes. More than half of these discontinuers (54.6%) reported discontinuing a GLP-1 RA within 6 months of initiation, and 79.7% reported discontinuation within 12 months of use. Approximately 1 in 7 (14.4%) reported sourcing GLP-1 RAs from a friend or family member, and more than half reported using a copayment coupon (35.4%) or free sample (22.0%). Many respondents (31.3%) reported first filling a prescription without insurance. Approximately 1 in 5 reported sourcing their medicine from a compounding pharmacy (9.8%) or Internet-based (9.1%) source. The most frequently cited reasons for discontinuation were cost (36.1%), side effects (33.3%), no insurance coverage (28.2%), and achieving a weight-loss goal (26.1%). Compared with those without diabetes, respondents with diabetes were significantly more likely to discontinue because of side effects (50.1% vs 28.1%, P = 0.0008). Respondents who reported sourcing their GLP-1 RA from a compounding pharmacy or Internet-based source were significantly more likely to discontinue because they perceived the medication to be ineffective compared with those who obtained their medication from a retail or mail-order pharmacy (17.5% vs 6.6%, P = 0.009). Neither diabetes status nor GLP-1 RA source was significantly associated with early discontinuation (<6 months). In this national survey, most US adults who stopped GLP-1 RAs did so within 6 months because of cost, adverse effects, lack of coverage, or having achieved a weight loss goal. Differences in coverage, costs, and sourcing are modifiable targets that may decrease high rates of GLP-1 RA discontinuation.

PMID 42504813
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-07-27

Kidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma: Biological Foundations and Emerging Clinical Applications.

Talao Jason King JK, Correa Rohann R, Gunaratnam Lakshman L, Fernandes Ricardo R

Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy characterized by variable clinical behavior and diverse molecular phenotypes. Although immune checkpoint inhibitors and targeted therapies have transformed the treatment landscape of advanced RCC, clinically validated biomarkers capable of improving risk stratification, therapeutic-decision making and disease monitoring remain lacking. Kidney injury molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor-1 (HAVCR1) or T-cell immunoglobulin and mucin domain-containing protein-1 (TIM-1), has emerged as a biologically compelling investigational biomarker e because of its close relationship to proximal tubular epithelial injury and renal carcinogenesis. KIM-1 is a transmembrane glycoprotein minimally expressed in normal kidney tissue but markedly upregulated in dedifferentiated proximal tubular epithelial cells following injury, and in clear cell RCC, where its extracellular domain can be shed into plasma and urine. Beyond its role as a marker of tubular injury, KIM-1 participates in immune regulation, phagocytosis, inflammatory signaling and tissue remodeling, supporting its potential relevance to tumor biology. Clinical studies have demonstrated associations between elevated circulating KIM-1 levels and RCC diagnosis, recurrence risk, and survival outcomes, particularly in localized and postoperative disease settings. KIM-1 has additionally been investigated as a therapeutic target through antibody-drug conjugate approaches. Despite promising translational data, important limitations yet remain. Current evidence is predominantly prognostic rather than predictive, and substantial analytical and biological challenges continue to limit implementation. Assay standardization, clinically meaningful cutoffs, specimen selection, timing of sampling, and confounding by chronic kidney disease or nonmalignant renal injury remain incompletely resolved. Furthermore, evidence supporting incremental value beyond established clinicopathologic models remains limited. This review critically evaluates the biological rationale, analytical considerations and clinical evidence supporting KIM-1 in RCC. Particular emphasis is placed on distinguishing prognostic, predictive, pharmacodynamic, and therapeutic applications, as well as defining the evidentiary gaps that must be addressed before clinical implementation. Current evidence is derived predominantly from retrospective and exploratory analyses, and important limitations remain regarding assay standardization, biological specificity, chronic kidney disease-related confounding, and prospective validation. The review concludes with a summary of the evolving landscape of KIM-1-directed biomarker strategies in RCC, which may ultimately contribute to improved biologic risk stratification and biomarker-driven clinical investigation in RCC.

PMID 42505180
阅读全文 →
PubMedThe Journal of international medical research2026-07-27

Reduced serum Sestrin-1 is associated with subclinical cardiovascular alterations in systemic lupus erythematosus: A controlled cross-sectional study.

Ucar Cahit C, Celik Mustafa M, Goktepe Mevlut Hakan MH, Yildizgoren Mustafa Turgut MT et al.

ObjectiveSystemic lupus erythematosus is associated with increased cardiovascular morbidity, even in the absence of overt clinical disease. Sestrin-1 is a stress-responsive antioxidant protein implicated in oxidative homeostasis and cardiovascular protection. This study aimed to evaluate serum Sestrin-1 levels in patients with systemic lupus erythematosus and examine their relationship with subclinical cardiovascular findings.MethodsIn this controlled cross-sectional study, 60 patients with systemic lupus erythematosus and 60 age-matched healthy controls underwent clinical assessment, laboratory testing, 12-lead electrocardiography, transthoracic echocardiography, and carotid intima-media thickness measurement. Serum Sestrin-1 was measured by enzyme-linked immunosorbent assay (ELISA). Between-group comparisons used parametric or nonparametric tests according to data distribution. Within the systemic lupus erythematosus cohort, correlations between Sestrin-1 and disease activity (Systemic Lupus Erythematosus Disease Activity Index), as well as cardiovascular parameters, were assessed. An exploratory multivariable logistic regression model including Sestrin-1, left atrial diameter, corrected QT interval, age, and sex was constructed to identify variables associated with case status.ResultsSerum Sestrin-1 levels were significantly lower in patients with systemic lupus erythematosus than in controls (9.99 ± 2.01 vs. 17.79 ± 5.11 ng/mL; p < 0.001). Patients with systemic lupus erythematosus had a significantly longer corrected QT interval (429.65 ± 32.42 vs. 376.26 ± 33.41 ms; p < 0.001). In the exploratory multivariable logistic regression analysis, lower Sestrin-1 (per 1ng/mL increase, odds ratio 0.63; 95% confidence interval: 0.54-0.75; p < 0.001), larger left atrial diameter (per 1 mm increase, odds ratio 1.13; 95% confidence interval: 1.06-1.22; p < 0.001)), and longer corrected QT interval (per 1ms increase, odds ratio 1.03; 95% confidence interval: 1.02-1.05; p < 0.001) were independently associated with systemic lupus erythematosus status.ConclusionPatients with systemic lupus erythematosus exhibit markedly reduced serum Sestrin-1 levels together with subclinical cardiovascular abnormalities. The inverse relationship between Sestrin-1 and left atrial diameter suggests a possible link between reduced antioxidant defense and early atrial remodeling in systemic lupus erythematosus. Sestrin-1 may represent a promising candidate biomarker for subclinical cardiovascular involvement in patients with systemic lupus erythematosus; however, prospective studies are needed to confirm its clinical utility.

PMID 42506918
阅读全文 →
PubMedGeroScience2026-07-27

LINE-1 CpG methylation in canine blood and cortical DNA tracks epigenetic changes with age.

Jónás Dávid D, Tátrai Kitti K, Egyed Balázs B, Kubinyi Eniko E

Aging is accompanied by progressive epigenetic alterations, including changes in DNA methylation affecting both gene-associated regions and repetitive elements such as LINE-1 retrotransposons. Reduced epigenetic repression of transposable elements has been implicated in age-related genomic instability. Circulating cell-free DNA (cfDNA) provides a minimally invasive substrate for monitoring systemic molecular changes; however, age-related LINE-1 methylation dynamics in cfDNA remain poorly characterized in non-human species. Dogs represent a valuable translational model for aging research due to their shared environment with humans and shorter lifespan. We investigated age-associated LINE-1 CpG methylation in plasma-derived cfDNA and in prefrontal cortex genomic DNA from dogs. Sequence analysis of 264 potentially active canine LINE-1 elements identified a highly conserved central region spanning ORF1 and ORF2, with the targeted CpG site located within a locally low-variability segment, supporting multi-copy assessment. Methylation was quantified using methylation-sensitive restriction endonuclease digestion followed by real-time quantitative PCR (MSRED-PCR), with bisulfite conversion-based PCR (BSC-PCR) used for technical validation. In clinically healthy dogs, LINE-1 methylation in blood cfDNA showed a strong negative association with chronological age, best described by a nonlinear (logarithmic) model. In prefrontal cortex samples, older dogs exhibited significantly lower LINE-1 methylation compared to younger individuals. Across tissues, aging was consistently associated with LINE-1 hypomethylation. These findings indicate that age-related LINE-1 hypomethylation is detectable in both brain tissue and circulating cfDNA. While based on cross-sectional cohorts, the results suggest that LINE-1 methylation in cfDNA may represent a candidate minimally invasive marker of chronological aging in dogs.

PMID 42503570
阅读全文 →
PubMedInsects2026-07-27

Native Entomopathogenic Fungi Against Whitefly (Bemisia tabaci) in Serrano Chili (Capsicum annuum L.).

Jiménez-Jiménez Magali M, Cabrera-Mireles Héctor H, Soto-Estrada Alejandra A, Gómez-Godínez Lorena Jacqueline LJ et al.

The whitefly (Bemisia tabaci) is a significant pest of chili crops, and the continuous use of insecticides to control it has led to insecticide resistance. This study aimed to characterize and evaluate the pathogenicity and virulence of native entomopathogenic fungus (EPF) strains from the Sotavento region against whiteflies in the laboratory. Fungi were isolated from whiteflies collected from chili plants in different habitats and identified through morphological and molecular characterization. The pathogenicity of nine EPF strains was assessed at 1 × 109 spores mL-1, while the virulence of the most pathogenic strains was evaluated from 1 × 104 to 1 × 109 spores mL-1. The lethal concentration (LC50) and lethal time (LT50) were also determined. Two native genera of EPF were identified: Beauveria and Cordyceps. The strains JV01 and PV02 (Cordyceps javanica), SV01 (Cordyceps fumosorosea), and MV03 (Beauveria bassiana) demonstrated high pathogenicity, causing mortality rates ranging from 94% to 100% at a concentration of 1 × 106 spores mL-1, five days after application. The strains JV01 and SV01 showed LC50 values of 1.65 × 105 and 5.53 × 105 spores mL-1, respectively, with an LT50 of 2 days for both. In conclusion, highly pathogenic and virulent native EPF strains were identified against adult whiteflies on serrano chili.

PMID 42505791
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多pancrelipase